Ali R. Jazirehi

Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab

Ali R. Jazirehi, Mario I. Vega, Devasis Chatterjee et al. · Cancer Research · 2004 · 188 citations

Medicine, Oncology, Pharmacology +17

Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

Ali R. Jazirehi, Sara Huerta‐Yépez, Genhong Cheng et al. · PubMed · 2005 · 178 citations

Medicine, Immunology, Pharmacology +17

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xL expression

Sara Huerta‐Yépez, Mario I. Vega, Ali R. Jazirehi et al. · Oncogene · 2004 · 164 citations

Life Sciences, Cell Biology, Oncology +17

Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy

Ali R. Jazirehi, Mario I. Vega, Benjamin Bonavida · Cancer Research · 2007 · 162 citations · Full text

Medicine, Oncology, Pharmacology +17

Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) Inhibits the Constitutive Nuclear Factor-κB Signaling Pathway in Non-Hodgkin's Lymphoma B-Cell Lines: Role in Sensitization to Chemotherapeutic Drug-induced Apoptosis

Ali R. Jazirehi, Sara Huerta‐Yépez, Genhong Cheng et al. · Cancer Research · 2005 · 144 citations · Full text

Medicine, Oncology, Pharmacology +17